Skip to main content

Noelia Díaz Troyano

Institutions of which they are part

Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

Noelia Díaz Troyano

Institutions of which they are part

Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

Projects

Detección precoz y estrategias preventivas del deterioro cognitivo en pacientes con epilepsia de reciente diagnóstico

IP: Elena Fonseca Hernandez
Collaborators: Manuel Toledo Argany, Laura Castillo Ribelles, Enric Bellido Castillo, Noelia Díaz Troyano, Samuel López Maza, Manuel Quintana Luque, Silvana Isabel Sarria Estrada
Funding agency: Instituto de Salud Carlos III
Funding: 196250
Reference: PI24/00862
Duration: 01/01/2025 - 31/12/2027

Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia (Clinical Biochemistry, Drug Delivery & Therapy, CB-DDT)

IP: -
Collaborators: José Antonio Arranz Amo, Raquel Barquin Del Pino, Laura Conesa Milian, Clara Ramírez Serra, Yolanda Villena Ortiz, Joan López Hellin, Albert Blanco Grau, Roser Ferrer Costa, Joaquin Seras Franzoso, Diego Baranda Martínez-Abasca, Laura Castillo Ribelles, Clara Carnicer Cáceres, Marina Giralt Arnaiz, Ana Gomez Garcia, Simon Schwartz Navarro, Pablo Gabriel Medina, Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia (Clinical Biochemistry, Drug Delivery & Therapy, CB-DDT), Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia (Clinical Biochemistry, Drug Delivery & Therapy, CB-DDT), Laura Castellote Bellés, Daniel Bravo Nieto, Luz María Cruz Carlos, Clara Sanz Gea, Alba Estela García Fernández, Maria del Pilar Reimundo Diaz-Fierros, Belen Garcia Prats, Noelia Díaz Troyano, JAUME VIMA BOFARULL, Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia (Clinical Biochemistry, Drug Delivery & Therapy, CB-DDT), Diana Fernandes de Rafael, Maria Francesca Cortese, Sandra Mancilla Zamora
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 60000
Reference: 2021 SGR 01173
Duration: 01/01/2022 - 30/06/2025

Estudio de la quasiespecies del gen X en ARN circulante del virus de la hepatitis B (ARN-VHB): en búsqueda de nuevos factores pronósticos y dianas para terapia génica

IP: -
Collaborators: Noelia Díaz Troyano
Funding agency: Instituto de Salud Carlos III
Funding: 60000
Reference: INT19/00060
Duration: 01/06/2020 - 30/06/2021

Related news

The annual event offered a space for dialogue between the scientific community and society on how to address the future of ageing through research and innovation.

Docetaxel, carried by Soluplus, proved to be the most effective and least toxic combination to cross the blood-brain barrier and attack the tumour directly.

Based on the study led by VHIR, a clinical trial has been approved for patients with locally advanced pancreatic cancer.

Related professionals

Ana Lain Fernandez

Ana Lain Fernandez

Bioengineering, Cell Therapy and Surgery in Congenital Malformations
Read more
Rebeca Blanch Garcia

Rebeca Blanch Garcia

Research technician
Gene Therapy at Nervous System
Read more
Jose Maria  Zuazo  Morquecho

Jose Maria Zuazo Morquecho

Liver Diseases
Read more
Leidy Alejandra Gonzalez Molano

Leidy Alejandra Gonzalez Molano

Research technician
Microbiome Research
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.